GS-9669

DRUG4 trials

Sponsors

Gilead Sciences, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Chronic HCV InfectionChronic Hepatitis CChronic Hepatitis C InfectionHepatitis C, Chronic

Phase 2

Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

CompletedNCT01260350

Gilead SciencesChronic Hepatitis C Infection

Start: 2010-12-31End: 2013-12-31Updated: 2014-11-17

Combination Therapy for Chronic Hepatitis C Infection

CompletedNCT01805882

National Institute of Allergy and Infectious Diseases (NIAID)Hepatitis C, Chronic

Start: 2013-01-31End: 2015-08-31Updated: 2017-06-08

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

CompletedNCT01826981

Gilead SciencesChronic Hepatitis C

Start: 2013-04-30End: 2015-05-31Updated: 2018-11-16

Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection

CompletedNCT01984294

Gilead SciencesChronic HCV Infection

Start: 2013-10-31End: 2014-07-31Updated: 2018-11-19

Related Papers

Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis.

2022-06-083 citations

Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.

2016-01-0121 citations

Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.

2015-11-2451 citations

Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens

Clinical Infectious Diseases2015-10-3151 citations

Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.

2015-08-07128 citations

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.

2015-07-14109 citations

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.

2015-01-13120 citations

Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.

2014-11-0151 citations

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.

2013-11-18143 citations

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

2013-01-01510 citations